The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Modulation of radiation biomarkers in a randomized phase II study of 131I-MIBG with or without radiation sensitizers for resistant/relapsed neuroblastoma.
 
Kevin M. Campbell
No Relationships to Disclose
 
Susan Groshen
No Relationships to Disclose
 
Araz Marachelian
Research Funding - Pfizer (Inst); United Therapeutics (Inst)
 
Sharmistha Pal
No Relationships to Disclose
 
Daphne A. Haas-Kogan
Leadership - CellWorks
Consulting or Advisory Role - Gerson Lehrman Group; Guidepoint Global; Leidos Biomedical Research; Sanofi; SRA International
Research Funding - Novartis (Inst)
Expert Testimony - Hallberg Law; Law Offices of Craig Cook
 
Mark Kellogg
Consulting or Advisory Role - Alexion Pharmaceuticals; Berg; Jana Care
Speakers' Bureau - Alexion Pharmaceuticals
 
Angela Clare Evans
No Relationships to Disclose
 
Matthew A. Coleman
No Relationships to Disclose
 
Julie R. Park
No Relationships to Disclose
 
Meaghan Granger
No Relationships to Disclose
 
Katherine K. Matthay
Honoraria - EUSA Pharma; Progenics
 
Steven G. DuBois
Research Funding - Bayer (Inst); Bristol-Myers Squibb (Inst); Curis (Inst); Eisai (Inst); Lilly (Inst); Loxo (Inst); Merck (Inst); Pfizer (Inst); Roche/Genentech (Inst); Salarius Pharmaceuticals (Inst); Turning Point Therapeutics (Inst)
Travel, Accommodations, Expenses - Roche/Genentech; Salarius Pharmaceuticals
(OPTIONAL) Uncompensated Relationships - Ymabs Therapeutics Inc